Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Coagulation Factor X (Human)
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BPL Receives Orphan Drug Marketing Authorization for Coagadex® in Mexico
Details : Coagadex® is the first and only treatment specifically for Hereditary Factor X Deficiency, a very rare inherited clotting disorder that causes problems with blood clotting due to not having enough Factor X in the blood.
Product Name : Coagadex
Product Type : Protein
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Coagulation Factor X (Human)
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
